What question did this study set out to answer?

To review clinical and pharmacological evidence for the efficacy of Nimba-Aragwadhadi Kashaya in managing type 2 diabetes mellitus.

April 1, 2026Open Access

Therapeutic Potential of Nimba-Aragwadhadi Kashaya for Type 2 Diabetes Mellitus: Bridging Classical Ayurvedic Wisdom With Modern Pharmacological Evidence - A Comprehensive Review

Key Points

To review clinical and pharmacological evidence for the efficacy of Nimba-Aragwadhadi Kashaya in managing type 2 diabetes mellitus.
Systematic review of classical Ayurvedic texts and peer-reviewed research.
Analysis of clinical trials and pharmacological studies from major databases.
Evaluation of individual constituents and their mechanisms of action.
Increased insulin secretion and sensitivity identified through specific mechanisms.
Notable reductions in HbA1c levels between 0.8-1.5% in clinical studies.
Demonstrated improvements in lipid profiles and reduced diabetic complications.

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) affects 589 million adults globally, with 101 million in India. Madhumeha, described in Ayurvedic texts as excessive sweet-tasting urination, correlates with T2DM. Nimba-Aragwadhadi Kashaya, a classical seven-herb formulation, has been prescribed for Prameha management for millennia. Objective: To systematically review clinical and pharmacological evidence supporting Nimba-Aragwadhadi Kashaya’s efficacy in T2DM management. Methods: Comprehensive review of classical Ayurvedic texts (Charaka Samhita, Sushruta Samhita, Sahasrayogam), peer-reviewed research, clinical trials, and pharmacological studies from databases including PubMed, Scopus, Web of Science through January 2025. Results: The formulation comprises Azadirachta indica (Nimba), Cassia fistula (Aragwadha), Alstonia scholaris (Saptaparna), Marsdenia tenacissima (Murva), Holarrhena antidysenterica (Kutaja), Myrica nagi (Somavriksha), and Butea monosperma (Palasha). Individual constituents demonstrate: (1) Enhanced insulin secretion via KATP channel modulation; (2) Improved insulin sensitivity through AMPK activation and NF-kB inhibition; (3) Pancreatic β-cell protection via antioxidant mechanisms (SOD increased 28-42%, catalase 32-38%, MDA decreased 39-47%) ; (4) Anti-inflammatory effects (TNF-α decreased 42%, IL-6 38%, CRP 42-45%) ; (5) Lipid-lowering properties. Clinical studies demonstrated HbA1c reductions of 0. 8-1. 5%, improved lipid profiles, and reduced diabetic complications. Bioactive compounds include alkaloids (nimbidin, conessine, berberine-like), flavonoids (quercetin, butein), terpenoids, and polyphenols. Conclusions: Nimba-Aragwadhadi Kashaya demonstrates promising multi-targeted therapeutic potential for T2DM with favorable safety profiles. The polyherbal formulation addresses insulin resistance, β-cell dysfunction, oxidative stress, and inflammation simultaneously. Large-scale randomized controlled trials with standardized preparations are essential for definitive clinical validation and integration into evidence-based diabetes care protocols.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Dr. Sumai M. A.1, Dr. Kumar Chaudappalavar2, Dr. Vishal Patil*3 (Wed,) studied this question.

synapsesocial.com/papers/69ccb7b016edfba7beb89ba9 https://doi.org/https://doi.org/10.5281/zenodo.19326465

Bookmark

View Full Paper